Table 2.
Detail of best nivolumab responses
| Responses | LTSs | Nivolumab treatment duration | ||
|---|---|---|---|---|
| (N = 65) |
<2 y (n = 47) |
2 y (n = 7) |
>2 y (n = 11) |
|
| Complete response, n (%) | 7 (10.8) | 5 (10.6) | 1 (14.3) | 1 (9.1) |
| Partial response, n (%) | 33 (50.8) | 19 (40.4) | 5 (71.4) | 9 (81.8) |
| Stable disease, n (%) | 21 (32.3) | 19 (40.4) | 1 (14.3) | 1 (9.1) |
| Progressive disease, n (%) | 4 (6.2) | 4 (8.5) | 0 (0) | 0 (0) |
| Not assessable, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Objective response rate (%) | 61.6 | 51 | 85.7 | 90.9 |
Results are expressed as n (%).
Abbreviation: LTSs, long‐term survivors.